Macrophage News and Research RSS Feed - Macrophage News and Research

A macrophage is a type of white blood cell that surrounds and kills microorganisms, removes dead cells, and stimulates the action of other immune system cells.
Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists identify long-overlooked function of vascular smooth muscle cells in atherosclerosis

Scientists at the Interfaculty Institute of Biochemistry (IFIB) have collaborated with colleagues from the Department of Pharmacy and the Department of Dermatology of the University of Tübingen to identify a long-overlooked function of vascular smooth muscle cells in atherosclerosis. [More]
Exploiting chemical response from body's immune system to attack pathogens using copper

Exploiting chemical response from body's immune system to attack pathogens using copper

Harnessing a natural process in the body that pumps lethal doses of copper to fungi and bacteria shows promise as a new way to kill infectious microbes, a team of scientists at Duke University report. [More]
Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever. [More]
Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Scientists build artificial cells programmed to eat their undesirable neighbors

Scientists build artificial cells programmed to eat their undesirable neighbors

A team of researchers has devised a Pac-Man-style power pellet that gets normally mild-mannered cells to gobble up their undesirable neighbors. The development may point the way to therapies that enlist patients’ own cells to better fend off infection and even cancer, the researchers say. A description of the work will be published July 15 in the journal Science Signaling. [More]
Inflammatory shift in long-standing bipolar disorder

Inflammatory shift in long-standing bipolar disorder

Patients with chronic bipolar disorder, but not those with schizophrenia, have a shift towards an M1 rather than an M2 macrophage response, research suggests. [More]
Clear advances in the fight against tuberculosis are within reach, say immunologists

Clear advances in the fight against tuberculosis are within reach, say immunologists

Leading immunologists expect to see some clear advances in the fight against tuberculosis, an infectious disease that is widespread the world over. Professor Stefan Kaufmann, Director at the Max Planck Institute for Infection Biology in Berlin, echoed these sentiments at today's launch of the scientific programme for the 64th Lindau Nobel Laureate Meeting at Lindau, Germany. [More]
Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinkers at greater risk of developing pneumonia and ARDS

Heavy drinking damages the body in many ways. In addition to liver failure, alcoholics are at a much greater risk of developing pneumonia and life threatening acute respiratory distress syndrome (ARDS), for which there is no treatment. [More]
Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Microparticles in crab, shrimp and lobster shells may help prevent inflammatory bowel disease

Yoshimi Shibata, Ph.D., professor of biomedical science in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has received a $380,552 grant from the National Institute of Complementary and Alternative Medicine of the National Institutes of Health to further investigate how microparticles called "chitin" found in crab, shrimp and lobster shells have anti-inflammatory mechanisms that could lead to the development of novel preventive and therapeutic strategies for individuals who suffer from inflammatory bowel disease (IBD) and others diseases. [More]
NIH receives $10 million grant for research on breast cancer metastasis

NIH receives $10 million grant for research on breast cancer metastasis

The American Cancer Society predicts that 40,000 American women will die from breast cancer this year. Most of those deaths will occur due to cells from the primary tumor that spread to other parts of the body-the process known as metastasis. [More]
Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014. [More]
CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma. [More]
Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. [More]
Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Study: E-cigarettes appear to increase virulence of drug- resistant and life-threatening bacteria

Despite being touted by their manufacturers as a healthy alternative to cigarettes, e-cigarettes appear in a laboratory study to increase the virulence of drug- resistant and potentially life-threatening bacteria, while decreasing the ability of human cells to kill these bacteria [More]
Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that principal investigator, Srdan Verstovsek, MD, PhD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 2, 2014 at the American Society for Clinical Oncology 2014 Annual Meeting. [More]
Inflammatory pneumococcal response differs by age

Inflammatory pneumococcal response differs by age

The composition of inflammatory lung infiltrate in people with pneumonia caused by Streptococcus pneumoniae differs by age, an in-situ study reveals. [More]
Debiopharm signs new license and research agreement with Yale University

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases. [More]
Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

Six-way jet-in-air sorter from Beckman Coulter Life Sciences delivers simultaneous high-speed cell sorting and sub-micron particle detection

MoFlo Astrios EQ, a six-way jet-in-air sorter from Beckman Coulter Life Sciences, delivers patent pending enhanced dual forward scatter (eFSC) technology for simultaneous sorting and detection of particles from 200 nm to 30 µm in diameter. The instrument sets a new standard for flow cytometry core facilities, delivering high-speed cell sorting and micro-particle detection in a single package. Featuring detailed and precise forward scatter resolution, beadless drop sample handling and increased biosafety, Astrios EQ meets a range of analysis needs. [More]
Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death. [More]